CXCR3 and triple-negative breast carcinoma: CXCL9 is a ligand for CXCR3, and both CD8+ T-cell infiltration and the therapeutic efficacy of dual PD-1/CTLA-4 blockade were shown to be CXCR3 dependent using a mouse model of triple-negative breast cancer [77].